Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cancer Monoclonal Antibodies Market Growth Potential: How Will Market Size Shift Through 2030?
The market for cancer monoclonal antibodies has experienced rapid expansion in recent years. Its size is projected to increase from $86.23 billion in 2025 to $98.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.8%. This historical growth can be attributed to several factors, including the initial limited access to monoclonal antibody therapies, a prior reliance on conventional chemotherapy, the rising incidence of breast and blood cancers, increasing physician understanding of targeted treatments, and the enlargement of hospital oncology departments.
The cancer monoclonal antibodies market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $166.92 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.2%. This expected growth throughout the forecast period is attributed to factors such as the introduction of new immuno-oncology monoclonal antibodies, the development of combination therapies, the increasing adoption of personalized cancer treatment methods, improvements in research laboratory capabilities, and a rise in investment allocated to clinical trials and biologics manufacturing. Prominent trends for the forecast period include the increasing uptake of targeted monoclonal antibody therapies for various cancer types, enhanced investment in immuno-oncology research and development efforts, the expansion of personalized and precision cancer treatment programs, growth in the infrastructure of hospitals and research laboratories dedicated to cancer therapy, and the integration of both combination therapies and novel biologics into cancer treatment protocols.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Monoclonal Antibodies Market Demand Drivers Opening New Revenue Streams
The increasing global incidence of cancer is expected to fuel the expansion of the cancer monoclonal antibody market. Cancer refers to a collection of illnesses characterized by the uncontrolled proliferation of abnormal cells, which can infiltrate tissues and metastasize throughout the body. The growing prevalence of cancer is primarily linked to an aging population, given that advanced age is the leading risk factor for developing most cancer types, with the majority of diagnoses found in individuals over 65 years old. Cancer monoclonal antibody therapies aid in cancer treatment by specifically identifying and attaching to tumor-associated antigens, thereby directly hindering cancer cell proliferation, marking malignant cells for destruction by the immune system, accurately delivering cytotoxic agents to tumors, and modifying the tumor microenvironment to bolster the body’s anti-cancer immune response. For example, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, indicates that in Australia, cancer diagnoses rose from 160,570 in 2022 to 164,694 in 2023, showing a significant increase during that period. This rising trend underscores the increasing occurrence of cancer within the nation. Globally, the four most frequently diagnosed types of cancer are lung, prostate, bowel, and female breast cancer, collectively making up 43 percent of all newly reported cancer cases. Consequently, the worldwide increase in cancer incidence rates is projected to stimulate demand for the growth of the cancer monoclonal antibody market.
Cancer Monoclonal Antibodies Market Segment Landscape And Growth Outlook
The cancer monoclonal antibodies market covered in this report is segmented –
1) By Monoclonal Antibody Therapies: Avastin, Herceptin,Keytruda, Opdivo, Darzalex, Perjeta, Others
2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor,Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others
3) By End-User: Hospitals, Research Laboratories, Others
Subsegments:
1) By Avastin: Colorectal Cancer Treatment, Lung Cancer Treatment, Renal Cell Carcinoma Treatment
2) By Herceptin: Breast Cancer Treatment, Gastric Cancer Treatment
3) By Keytruda: Melanoma Treatment, Non-Small Cell Lung Cancer (NSCLC) Treatment, Head And Neck Cancer Treatment
4) By Opdivo: Melanoma Treatment, Renal Cell Carcinoma Treatment, Hodgkin Lymphoma Treatment
5) By Darzalex: Multiple Myeloma Treatment, AL Amyloidosis Treatment
6) By Perjeta: Breast Cancer Treatment, Neoadjuvant Therapy For HER2-Positive Breast Cancer
7) By Others: Cetuximab (Erbitux) For Colorectal And Head And Neck Cancers, Rituximab (Rituxan) For Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia, Atezolizumab (Tecentriq) For Various Cancers
Cancer Monoclonal Antibodies Market Trends Powering Strategic Industry Growth
Leading companies active in the cancer monoclonal antibodies market are concentrating on technological progress in oncology, specifically bispecific antibody technology, to engage T-cells in targeting malignant B-cells. Bispecific antibody technology describes engineered antibodies capable of binding simultaneously to two antigens, thereby facilitating precise immune activation against cancer cells. For instance, in May 2023, AbbVie Inc., a U.S.-based biopharmaceutical company, secured FDA accelerated approval for and launched EPKINLY (epcoritamab-bysp). This therapeutic option addresses adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after two or more prior systemic therapies, employing bispecific antibody technology to recruit T-cells for a focused and innovative method of treating lymphoma.
Cancer Monoclonal Antibodies Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the cancer monoclonal antibodies market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc, Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Gilead Sciences, Eurofarma, BIONOVIS BRASIL, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Genzyme
View The Full Cancer Monoclonal Antibodies Market Report:
Cancer Monoclonal Antibodies Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the cancer monoclonal antibodies market in 2025. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
